Expansion Opportunity Velocity is rapidly expanding its footprint in Europe with site acquisitions and operational enhancements, presenting cross-border trial opportunities for sponsors seeking diverse regulatory regions and faster enrollment.

Feasibility Advantage The newly launched Feasibility Agent leverages longitudinal site and performance data across 70+ global sites, offering a compelling pitch to sponsors for site selection, enrollment forecasting, and study startup acceleration.

Strategic Partnerships Recent collaborations with SlopeClinical and Palantir highlight Velocity’s focus on inventory management efficiency and data-powered trial operations, creating upsell avenues in data integration, analytics, and financial administration of trials.

Revenue Growth With a revenue range of 250–500 million and a large, global investigator network, Velocity is positioned to pursue larger multicenter trials and complex studies that require scalable site coordination and high-quality data capture.

Thought Leadership Active engagement in vaccine policy discussions and executive-level events signals opportunities to offer sponsor-focused programs, rare disease or vaccine-centric study design support, and premium feasibility services to high-priority therapeutic areas.